Evaluation the Diagnostic Value of CXCL-13 & anti-CarP with RF & ACCP

CHF 84.35
Auf Lager
SKU
BS18JIRI9K9
Stock 1 Verfügbar
Geliefert zwischen Mi., 25.02.2026 und Do., 26.02.2026

Details

The study revealed a highly significant difference of CXCL13, Anti-CarP, Anti-CCP, and RF levels between RA patients and controls at p value =0.000. CXCL13 demonstrated good specificity (83%) and high sensitivity (93%) for RA patients, while Anti-CarP antibodies demonstrated low sensitivity(39%) and high specificity(98%) for diagnosis of RA. Patients with RA have positivity of 71.7% and 36.7% for RF and Anti-CarP, respectively, while healthy group have 11.7% and 1.7% respectively. The serum levels of CXCL13, anti-CarP and ACCP did not significantly correlate with DAS28-ESR and CDAI, indicating that these biomarkers are not effective in predicting the activity of RA.

Autorentext

I am an immunologist, with a PhD degree in medical microbiology, immunology and a member of the teaching staff (Assistant Professor) of the Department of Medical Microbiology/College of Medicine/University of Kufa.

Weitere Informationen

  • Allgemeine Informationen
    • GTIN 09786207650323
    • Sprache Englisch
    • Größe H220mm x B150mm x T9mm
    • Jahr 2024
    • EAN 9786207650323
    • Format Kartonierter Einband
    • ISBN 6207650328
    • Veröffentlichung 28.05.2024
    • Titel Evaluation the Diagnostic Value of CXCL-13 & anti-CarP with RF & ACCP
    • Autor Thanaa Al-Turaihi , Ghasak Ali
    • Untertitel In Rheumatoid Arthritis Patients
    • Gewicht 238g
    • Herausgeber LAP LAMBERT Academic Publishing
    • Anzahl Seiten 148
    • Genre Medical Books

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470
Kundenservice: customerservice@avento.shop | Tel: +41 44 248 38 38